Compared with less-intensive glucose control, more intensive glucose control was indeed found to reduce the risk of major adverse cardiovascular events (MACEs) by 9% (HR 0.91 [95% CI 0.84, 0.99]) in previous trials largely based on metformin, sulfonylureas and insulin therapy [3]
(And gettin caught in the rain.) or something like this: The XYZ Doohickey Company was founded in 1971, and has been providing quality doohickeys to the public ever since
Mounjaro is a onceweekly injectable medicine whose active ingredient is tirzepatide
Unlike semaglutide, which only targets GLP-1, tirzepatide activates both incretin pathwaysdelivering significantly greater weight loss in clinical trials
Decision timeline Timelines vary by goal, dose, baseline health, and consistency